FDA Extends Ruxolitinib Cream Review Period for Pediatric AD ...Middle East

Medscape - News
FDA Extends Ruxolitinib Cream Review Period for Pediatric AD
The supplemental application is based on data from a phase 3 study of children aged 2-12 years with mild-to-moderate AD, randomly assigned to 0.75% or 1.5% ruxolitinib or a vehicle. Medscape Medical News

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Extends Ruxolitinib Cream Review Period for Pediatric AD )

Apple Storegoogle play

Also on site :